SJEPD030782_D1.RNA-Seq
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- age_years
- 3.98
- e1_e2
- E2
- umap1_2d
- -5.555997321
- umap2_2d
- 2.021875578
- umap1_3d
- -1.064135722
- umap2_3d
- 4.059431496
- umap3_3d
- -0.678109391
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.350
- NOTCH_SIGNALING+0.350
- MITOTIC_SPINDLE+0.340
- UV_RESPONSE_DN+0.320
- HYPOXIA+0.300
- MTORC1_SIGNALING+0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.280
- INFLAMMATORY_RESPONSE+0.270
- CHOLESTEROL_HOMEOSTASIS+0.250
- E2F_TARGETS+0.240
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.490
- DNA_REPAIR-0.330
- BILE_ACID_METABOLISM-0.310
- INTERFERON_GAMMA_RESPONSE-0.300
- PEROXISOME-0.240
- COAGULATION-0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.170
- FATTY_ACID_METABOLISM-0.160
- MYC_TARGETS_V2-0.150
- ADIPOGENESIS-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD032263_D1.RNA-Seq | EPN | Anaplastic EPN | 0.834 |
| 2 | TCGA-85-8353-01A-21R-2296-07 | — | cohortSQ1 | 0.761 |
| 3 | MNG56 | — | — | 0.758 |
| 4 | TCGA-85-A50M-01A-21R-A262-07 | — | cohortSQ1 | 0.755 |
| 5 | TCGA-96-7544-01A-11R-2045-07 | — | cohortSQ1 | 0.731 |
| 6 | TCGA-BH-A1FU-01A-11R-A14D-07 | — | C | 0.730 |
| 7 | SJEPD032038_D1.RNA-Seq | EPN | Supratentorial EPN | 0.721 |
| 8 | DRR168609 | — | — | 0.720 |
| 9 | TCGA-56-7582-01A-11R-2045-07 | — | cohortSQ2 | 0.718 |
| 10 | ERR2278858 | — | — | 0.716 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.350 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.340 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.270 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.250 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.240 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.150 | Idelalisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |